Active Not Recruiting
PHASE1
INTERVENTIONAL
NCT06297616
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.
Interventions
Name:
LY3841136
Type:
DRUG
Description:
Administered SC
Name:
LY3841136-Placebo
Type:
DRUG
Description:
Administered SC
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Tirzepatide-Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Part A: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 22
TimeFrame:
Baseline through Week 22
Description:
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Measure:
Part B: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration at Week 34
TimeFrame:
Baseline through Week 34
Description:
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Trial Information
NCT ID
NCT06297616
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025